In this review the authors describe the epidemiology, mechanisms, detection and management of drug-induced liver injury with particular concern to old age. They argue that monitoring for clinical response is essential to optimize efficacy and reduce toxicity. They warn that the detection of adverse effects of medications in older patients can be complicated by nonspecific presentation as geriatric syndromes.
These guidelines are largely based on the issues raised during the European Association for the Study of Liver monothematic conference on Alcoholic Liver Disease in 2010. The guidelines have three main aims: (1) to provide physicians with clinical recommendations; (2) to emphasize the fact that alcohol can cause several liver diseases (steatosis, steatohepatitis, cirrhosis), all of which may coexist in the same patient; (3) to identify areas of interest for future research, including clinical trials.
Although liver disease is stereotypically linked to alcohol or drugs, the truth is that there are over 100 known forms of liver disease caused by a variety of factors and affecting everyone from infants to older adults. This website provides information about liver disease, liver health and resources and links for health care professionals.
The authors claim that non-alcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disease all over the world. The objective of their study was to evaluate the association between dietary vitamin C intake and NAFLD.
The American Association for the Study of Liver Diseases has approved the creation of two separate Special Interest Groups. While there are many areas ofoverlap between the two, both fields are in a phase of tremendous growth that could benefit from more individualized attention. Members are of AASLD areinvited to join SIGs by visiting http://www.aasld.org/membership/special-interest-groups
Recent studies have demonstrated that the efficacy of interferon-free direct-acting antiviral agents (DAAs) in patients over 70 is similar to that of younger age groups. Evidence continues to mount that life expectancy (LE) increases with successful treatment of hepatitis C (HCV) patients with advanced fibrosis. The evidence in older people is more limited.
The authors explain how the liver is the only internal human organ capable of natural regeneration of lost tissue. They argue that understanding how aging could affect the molecular pathology of liver diseases is particularly important.
This poster suggests that transplant, resection and ablation are potentially curative treatments for hepatocellular carcinoma (HCC) with limited outcome data in young-old (65-74) and older (≥75) patients.
This report of a study which covered liver tests for abnormal levels of asparate transaminase (AST), alkaline phosphatase (ALP) and bilirubin, with patients being followed up for an average of just over seven years. The elderly patients with the abnormal liver tests were compared with patients with normal liver tests. Key findings included that one in six people over 75 are likely to have at least one abnormal liver test and those that have two or more are twice as likely to die from cancer and 17 times more likely to die from liver disease.